Keywords
Tocilizumab
Efficacy
Tolerance
Categories
How to Cite
Abstract
Introduction: The aim of this study was to evaluate in “real life” the efficacy and the tolerance of Tocilizumab (TCZ) in the treatment of rheumatoid arthritis (RA).
Materials and methods: A cross-sectional study including patients with RA patients treated with TCZ at the commended dose of 8 mg/kg/ 4 weeks. The therapeutic response was evaluated by the EULAR DAS 28 ‐CRP/ VS at month 3 and month 6 of treatment.
Results: RA was in most cases severe (76,5 %), seropositive (88,2 %) and erosive (81,3 %). TCZ was prescribed as an alternative to a previous biotherapy in 23 % of the patients and in monotherapy in 76, 5 % of the patients. After treatment follow-up at 3 and 6 months, the different parameters observed were significantly improved including: VAS (visual analogue scale) pain (p=0,000), CRP (mg/L) p=0,000), ESR (mmH1) (p=0,000), DAS 28 CRP (p=0,000), and DAS 28 ESR (p=0,000). Apart from a worsening of renal function in a patient contraindicated continuation of tocilizumab, no serious side effects were noted.
Conclusion: Our study confirmed the efficacy and tolerance of TCZ therapy in Moroccan patients suffering from RA.
Keywords: rheumatoid arthritis, tocilizumab, efficacy, tolerance
References
Ghita Harifi, Emmanuel Chatelus, Christelle Sordet, Jacques-Eric Gottenberg, Jean Sibilia. De nouvelles cibles cytokiniques dans la polyarthrite rhumatoïde : le tocilizumab et les autres inhibiteurs des cytokines. Rev Rhumat. 2010 May; 77(1): s32-s40. https://doi.org/10.1016/S1169-8330(10)70006-5
Nishimoto N, Yoshizaki K, Maeda K, Kuritani T, Deguchi H, Sato B, et al. Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. J Rheumatol. 2003 Jul;30 (7):1426-35. [Accessed 01 Jul 2021]. Available from : https://www.jrheum.org/content/30/7/1426.short
Clément Chopin, Loïc Pauvele, Sarah Jaulerry, Pascal Brochot, Jean-Paul Eschard, Jean-Hugues Salmon et al. [Effectiveness, therapeutic maintenance and reasons for stopping tocilizumab (TCZ): A retrospective and monocentric study in 88 patients followed for rheumatoid arthritis (RA) at the Reims university hospital]. Thérapie. May-June 2018; 73 (3): 231-236. https://doi.org/10.1016/j.therap.2017.08.004
Kihara M, Davies R, Kearsley-Fleet L, Watson KD, Lunt M, Symmons DP, et al. Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis. Clin Rheumatol. 2017 Feb;36(2):241-250. https://doi.org/10.1007/s10067-016-3485-5
Lannone F, Ferraccioli G, Sinigaglia L, Favalli EG, Sarzi-Puttini P, Atzeni F et al. Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics' register GISEA. Clin Rheumatol. 2018 Feb;37(2):315-321. https://doi.org/10.1007/s10067-017-3846-8
Choy EH, Bernasconi C, Aassi M, Molina JF, Epis OM. Treatment of Rheumatoid Arthritis WithAnti-Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study. Arthritis Care Res (Hoboken). 2017 Oct; 69(10):1484-1494. https://doi.org/10.1002/acr.23303
Nakashima Y, kondo M, Harada H, Horiuchi T, Ishinishi T, Jojima Y, et al. Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in combination with methotrexate. Modern Rheumatol. 2010 Aug; 20(4):343-52. https://doi.org/10.1007/s10165-010-0290-x
Bykerk VP, Ostör AJ, Alvaro-Gracia J, Pavelka K, Ivorra JA, Graninger W, et al. Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice. Ann Rheum Dis. 2012; 71(12):1950-1954. http://dx.doi.org/10.1136/annrheumdis-2011-201087
Burmester GR, Feist E, Kellner H, Braun J, Iking-Konert C, Rubbert-Roth A. Effectiveness and safety of the interleukin-6 receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIb real-life study (TAMARA). Ann Rheum Dis. 2011 May; 70(5): 755-9. https://doi.org/10.1136/ard.2010.139725
Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. Ann Rheum Dis, 2010 Jan; 69(1): 88-96. https://doi.org/10.1136/ard.2008.105197
Yamanaka H, Tanaka Y, Inoue E, Hoshi D, Momohara S, Hanami K, et al. Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study). Mod Rheumatol. 2011 Apr;21 (2):122-33. https://doi.org/10.1007/s10165-010-0366-7
Genovese MC, Rubbert-Roth A, Smolen JS, Kremer J, Kraishi M, Gómez-Reino J, et al. Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure. J Rheumatol. 2013 Jun; 40(6):768-80. https://doi.org/10.3899/jrheum.120687
Uda H, Saiki O. Tocilizumab Infusion Intervals Can be Extended to 5 or 6 Weeks in RA Patients Who Sustained Low Disease Activity By 4 Weeks Interval of Tocilizumab Infusion. Arthritis Rheumatol. 2016 Sep; 68. [Available 1 Jul 2021]. Available From: https://acrabstracts.org/abstract/tocilizumab-infusion-intervals-can-be-extended-to-5-or-6-weeks-in-ra-patients-who-sustained-low-disease-activity-by-4-weeks-interval-of-tocilizumab-infusion/
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2019 Nessrine Akasbi et al.
